secwatch.observer — SEC 8-K summary
======================================

Issuer:     Hepion Pharmaceuticals, Inc. (HEPA)
CIK:        0001583771
Form:       8-K
Filed at:   2026-04-14T23:59:59+00:00
Accession:  0001493152-26-016557
Event type: leadership
Sentiment:  neutral
Materiality: 0.55
Item codes: 1.01, 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Hepion Pharma CEO Kaouthar Lbiati resigns; separation agreement provides $225K payment
--------------------------------------------------------------------------------

- Separation agreement pays Dr. Lbiati $225,000, $30,625 pro-rata bonus, and 6 months COBRA reimbursement.
- Lbiati resigned as CEO on March 16, 2026, and as director on April 13, 2026.
- Gary Stetz serves as Interim CEO effective from the separation date.
- Separation includes a general release and confidentiality covenant.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1583771/000149315226016557/0001493152-26-016557-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1583771/000149315226016557/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-016557

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer